Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R McKay

Showing results (851-860 of 932) with videos related to

Pageof 94
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984Joseph W Kim, Rana R McKay, Marc R Radke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical OutcomesJustin Hwang, Xiaolei Shi, Andrew Elliott, et al.
JAMA Network Open|September 18, 2023
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate CancerClara Hwang, Nicholas C Henderson, Shih-Chun Chu, et al.
Cancer Immunology Research|June 6, 2023
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell CarcinomaRenee Maria Saliby, Talal El Zarif, Ziad Bakouny, et al.
Immunity|April 3, 2026
Distinct tissue niches contribute to prostate tissue-resident memory CD8<sup>+</sup> T cell differentiation and heterogeneityKennidy K Takehara, Alexander Monell, Vida Luna, et al.
The New England Journal of Medicine|July 1, 2026
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell CarcinomaToni K Choueiri, Robert J Motzer, Jose A Karam, et al.
JCO Precision Oncology|December 5, 2025
Impact of <i>SPOP</i> Mutations on Clinical Outcomes in Metastatic Prostate CancerDeepak Kilari, Nicholas C Henderson, Kyra Yamamoto, et al.
JAMA Network Open|April 15, 2026
Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell CarcinomaMartin Zarba, Eddy Saad, Karl Semaan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2021
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate CancerJamie M Sperger, Hamid Emamekhoo, Rana R McKay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial CancerPeter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, et al.
Pageof 94

Showing results (851-860 of 932) with videos related to

Sort By:
Pageof 94
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984Joseph W Kim, Rana R McKay, Marc R Radke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical OutcomesJustin Hwang, Xiaolei Shi, Andrew Elliott, et al.
JAMA Network Open|September 18, 2023
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate CancerClara Hwang, Nicholas C Henderson, Shih-Chun Chu, et al.
Cancer Immunology Research|June 6, 2023
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell CarcinomaRenee Maria Saliby, Talal El Zarif, Ziad Bakouny, et al.
Immunity|April 3, 2026
Distinct tissue niches contribute to prostate tissue-resident memory CD8<sup>+</sup> T cell differentiation and heterogeneityKennidy K Takehara, Alexander Monell, Vida Luna, et al.
The New England Journal of Medicine|July 1, 2026
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell CarcinomaToni K Choueiri, Robert J Motzer, Jose A Karam, et al.
JCO Precision Oncology|December 5, 2025
Impact of <i>SPOP</i> Mutations on Clinical Outcomes in Metastatic Prostate CancerDeepak Kilari, Nicholas C Henderson, Kyra Yamamoto, et al.
JAMA Network Open|April 15, 2026
Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell CarcinomaMartin Zarba, Eddy Saad, Karl Semaan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2021
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate CancerJamie M Sperger, Hamid Emamekhoo, Rana R McKay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial CancerPeter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, et al.
Pageof 94